Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joelle Guilhot

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Current Hematologic Malignancy Reports|March 14, 2012
Curing chronic myeloid leukemiaDelphine Rea, Philippe Rousselot, Joelle Guilhot, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2019
Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemiaFrédéric Millot, Natacha Maledon, Joelle Guilhot, et al.
Pediatrics|July 5, 2005
Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemiaFrédéric Millot, Philippe Traore, Joelle Guilhot, et al.
Journal of Pediatric Hematology/Oncology|March 21, 2002
Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemiaFrédéric Millot, Pauline Brice, Noel Philippe, et al.
Cancer|October 10, 2013
Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemiaHyacinthe Johnson-Ansah, Joelle Guilhot, Philippe Rousselot, et al.
Pediatric Blood & Cancer|December 1, 2005
Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemiaFrédéric Millot, Joelle Guilhot, Brigitte Nelken, et al.
American Journal of Hematology|September 19, 2012
Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 studyPhilippe Rousselot, Pascale Cony-Makhoul, Franck Nicolini, et al.
Blood|March 24, 2012
The EUTOS CML score aims to support clinical decision-makingVerena Hoffmann, Michele Baccarani, Joerg Hasford, et al.
Blood|May 4, 2011
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Michele Baccarani, Verena Hoffmann, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2020
Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped StudyDeborah Meyran, Arnaud Petit, Joelle Guilhot, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Current Hematologic Malignancy Reports|March 14, 2012
Curing chronic myeloid leukemiaDelphine Rea, Philippe Rousselot, Joelle Guilhot, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2019
Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemiaFrédéric Millot, Natacha Maledon, Joelle Guilhot, et al.
Pediatrics|July 5, 2005
Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemiaFrédéric Millot, Philippe Traore, Joelle Guilhot, et al.
Journal of Pediatric Hematology/Oncology|March 21, 2002
Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemiaFrédéric Millot, Pauline Brice, Noel Philippe, et al.
Cancer|October 10, 2013
Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemiaHyacinthe Johnson-Ansah, Joelle Guilhot, Philippe Rousselot, et al.
Pediatric Blood & Cancer|December 1, 2005
Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemiaFrédéric Millot, Joelle Guilhot, Brigitte Nelken, et al.
American Journal of Hematology|September 19, 2012
Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 studyPhilippe Rousselot, Pascale Cony-Makhoul, Franck Nicolini, et al.
Blood|March 24, 2012
The EUTOS CML score aims to support clinical decision-makingVerena Hoffmann, Michele Baccarani, Joerg Hasford, et al.
Blood|May 4, 2011
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Michele Baccarani, Verena Hoffmann, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2020
Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped StudyDeborah Meyran, Arnaud Petit, Joelle Guilhot, et al.
Pageof 3